An expanded-access, open-label study of the safety and tolerability of PEGASYS alone and in combination with ribavirin in patients with chronic hepatitis C.
Phase of Trial: Phase IV
Latest Information Update: 18 Nov 2010
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Roche